CEO provides updates on Oyster Point’s pipeline
To note: This transcript has been lightly edited for clarity.
Jeff Nau, PhD, MMS: Hi, I’m Jeff Nau. I’m the president and CEO of Oyster Point Pharmaceuticals. We are located in Princeton, New Jersey. And I’m here at the Eyecelerator 2022 meeting, and I wanted to give an update because we’ve been a year since the launch of Tyrvaya: last October we received our FDA approval, and in November we launched the product in the US market. . We had a great year with great market success. We are truly thrilled with the expanded patient access we have been able to provide and the market adoption by all dry eye practitioners.
This year, at the end of the year, we will have a report on our Olympia phase 2 trial, which concerns neurotrophic keratopathy. And so we are looking to expand our label in the future with dry eye as well as neurotrophic keratopathy. And we look forward to also presenting data on our expanding gene therapy pipeline in the future. So I want to thank everyone for joining us here at Eyecelerator.
So the new developments we’re working on are really focused on treating diseases of the ocular surface, but we’re doing it in a way that we can actually deliver it in new ways. Our product is therefore the first and only nasal spray to treat dry eye. It is therefore not a drop more than we deliver to the ocular surface. And then in our pipeline, when we think about our gene therapy program, we use gene therapy to harness the power of the lacrimal gland. And when we transduce the lacrimal gland, we can actually use the lacrimal gland as a drug delivery device to deliver therapeutic proteins, enzymes, and peptides to the ocular surface. So we’re really trying to develop a new era where we go beyond the drop and move into new delivery mechanics.